US20110060606A1 - Libraries and data structures of materials removed by debulking catheters - Google Patents
Libraries and data structures of materials removed by debulking catheters Download PDFInfo
- Publication number
- US20110060606A1 US20110060606A1 US12/880,010 US88001010A US2011060606A1 US 20110060606 A1 US20110060606 A1 US 20110060606A1 US 88001010 A US88001010 A US 88001010A US 2011060606 A1 US2011060606 A1 US 2011060606A1
- Authority
- US
- United States
- Prior art keywords
- computer readable
- readable media
- patient
- tissue
- data field
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/02—Instruments for taking cell samples or for biopsy
- A61B10/04—Endoscopic instruments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/02—Instruments for taking cell samples or for biopsy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/02—Instruments for taking cell samples or for biopsy
- A61B10/0233—Pointed or sharp biopsy instruments
- A61B10/0266—Pointed or sharp biopsy instruments means for severing sample
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B17/320758—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions with a rotating cutting instrument, e.g. motor driven
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B17/320783—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions through side-hole, e.g. sliding or rotating cutter inside catheter
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/0096—Casings for storing test samples
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B17/320725—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions with radially expandable cutting or abrading elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00743—Type of operation; Specification of treatment sites
- A61B2017/00778—Operations on blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B17/320783—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions through side-hole, e.g. sliding or rotating cutter inside catheter
- A61B2017/320791—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions through side-hole, e.g. sliding or rotating cutter inside catheter with cutter extending outside the cutting window
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/90—Identification means for patients or instruments, e.g. tags
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Definitions
- the present invention relates generally to computer readable media for storing data relating to patients and tissue samples excised from their vascular or other lumens.
- the data may be used to analyze current, past, or future patient health, to assess treatments, to evaluate drugs, to evaluate risk factors, and to determine proposed treatments or assessments.
- Atherosclerosis occurs naturally as a result of aging, but may also be aggravated by factors such as diet, hypertension, heredity, vascular injury, and the like. Atheromatous and other vascular deposits restrict blood flow and can cause ischemia which, in acute cases, can result in myocardial infarction. Atheromatous deposits can have widely varying properties, with some deposits being relatively soft and others being fibrous and/or calcified. In the latter case, the deposits are frequently referred to as plaque.
- Endoluminal stents are commonly used to treat obstructed or weakened body lumens, such as blood vessels and other vascular lumens. Once deployed in the blood vessel, the stent can remain in the body lumen where it will maintain the patency of the lumen and/or support the walls of the lumen which surround it.
- One factor impeding the success of stent technology in endoluminal treatments is the frequent occurrence of in-stent restenosis, characterized by proliferation and migration of smooth muscle cells within and/or adjacent to the implanted stent, causing reclosure or blockage of the body lumen.
- Atherectomy catheters intended to excise material from the blood vessel lumen generally employ a rotatable and/or axially translatable cutting blade which can be advanced into or past the occlusive material in, order to cut and separate such material from the blood vessel lumen.
- One aspect of the invention provides one or more computer readable media having a data structure stored thereon.
- the data structure comprises a first data field comprising a value corresponding to a property of a first tissue sample excised from a vascular lumen of a patient and a second data field comprising data identifying the patient.
- Optional additional data fields include a third data field comprising a value corresponding to cardiac health of the patient, a fourth data field comprising a value corresponding to a characteristic of the patient's blood, a fifth data field comprising a value corresponding to family history of the patient, a sixth data field comprising a value corresponding to the patient's medical history, a seventh data field comprising a value corresponding to a property of a second tissue sample excised from a vascular lumen of the patient at a distinct time, an eighth data field comprising a value corresponding to a property of a second tissue sample excised from distinct vascular lumen of the patient on the same day as the first tissue sample, a ninth data field which comprises a value which links a labeled storage container comprising excised tissue with a value in the second data field, a tenth data field which comprises a value which links the labeled storage containers comprising a component extracted or processed from an extracted tissue with a value in the second data field.
- a ninth data field which comprises
- FIG. 1 shows relevant markers for which the excised vascular material can be tested for expression, and about which data can be stored.
- Data collected related to samples of materials removed from body lumens can be stored in data structures.
- the stored data can be used to draw correlations, to stratify groups of patients, to provide risk assessments, to provide diagnoses and/or prognoses.
- Libraries of samples can be assembled to be used for studies of drugs, candidate drugs, toxins, therapeutic treatments, etc.
- the samples can be preserved according to any method known in the art. Samples may be frozen, for example, in liquid nitrogen. They may be preserved in paraffin, dried, freeze dried, etc. Samples may be treated to achieve a purified or semi-purified component of the sample. Samples may be treated, for example to extract DNA or protein. Samples may be treated to extract mRNA and to preserve it or “convert” it to cDNA. Desirably, samples are stored in a consistent and systematic way so that patient information remains associated with the samples so that patient outcome or other data collected at a later time can be associated with the sample concurrently or at a later time.
- Samples within a library can be stored and associated with information related to the sample itself, e.g., its properties, and the patient from whom the sample was excised.
- Other information that can be associated with the sample include results of analyses of the sample, patient history information, patient outcome information, drug efficacy information, therapeutic efficacy information, family history, factors of the patient related to cardiac disease, factors of the patient related to non-cardiac disease. In some cases this information may be stored without association with the physical samples.
- Patient identifying information may be coded so that confidentiality can be maintained while still permitting correlation of various patient attributes with the samples.
- One or more aspects of the invention may be embodied in computer-usable data and computer-executable instructions, such as in one or more program modules, executed by one or more computers or other devices.
- program modules include routines, programs, objects, components, data structures, etc. that perform particular tasks or implement particular abstract data types when executed by a processor in a computer or other device.
- the computer executable instructions may be stored on a computer readable medium such as a hard disk, optical disk, removable storage media, solid state memory, RAM, etc.
- the functionality of the program modules may be combined or distributed as desired in various catheters.
- the functionality may be embodied in whole or in part in firmware or hardware equivalents such as integrated circuits, field programmable gate arrays (FPGA), and the like.
- Particular data structures may be used to more effectively implement one or more aspects of the invention, and such data structures are contemplated within the scope of computer executable instructions and computer-usable data described herein.
- a first data field comprises a value corresponding to a property of a first tissue sample excised from a vascular lumen of a patient.
- the tissue sample is typically material that has been excised from a body lumen.
- the body lumen is often a vascular lumen.
- the property may be, for example, level of a marker in the tissue, composition of the tissue sample, histologic characterization, immunochemical characterization of the tissue, a genomic characteristic of the tissue, level of a mRNA in the tissue, location of the vascular lumen from which the tissue was excised, or volume or mass of the excised tissue. Any property of the tissue may be stored in this data field.
- a second data field may comprise data identifying a patient.
- the patient data may be anonymous or identify a person. If anonymous, the code will uniquely identify a patient's characteristics, without actually identifying the patient. Thus data can be used for studies, without divulging identities of the patients.
- An optional third data field comprises a value corresponding to cardiac health of the patient. Such values may, for example, relate to past infarct history, past angioplasty procedures, or past cholesterol values.
- a possible fourth data field comprises a value corresponding to a characteristic of the patient's blood. The blood may have been withdrawn at the time of or before tissue excision. The blood characteristic may be any known in the art, including but not limited to, sedimentation rate, red blood cell count, white blood'cell count, triglycerides, and C-reactive protein.
- An optional fifth data field comprises a value corresponding to family history of the patient.
- a value can be assigned to family history events based on degree of relatedness of the family member and the severity of the event.
- An optional sixth data field comprises a value corresponding to the patient's own medical history. This history includes but is not limited to cardiac related events. Thus other medical history events can be recorded which may not be currently known to be associated with vascular occlusion, but which may in fact have a correlation. Such data will make the data structure useful for discovering new associations, risks, and mechanisms. Such data may also be useful in stratifying patients for treatment regimens and for drug trials.
- An optional seventh data field comprises a value corresponding to a property of a second tissue sample excised from a vascular lumen of the patient at a distinct time from the first tissue sample.
- the second tissue sample can be excised from the same vascular lumen as the first tissue sample or from a different vascular lumen of the patient.
- An optional eighth data field comprises a value corresponding to a property of a second tissue sample excised from a distinct vascular lumen of the patient on the same day as the first tissue sample.
- the computer readable media can optionally be associated with one or more excised tissue samples in labeled storage containers.
- Labeled storage containers includes storage containers that are in fixed positions or parts of a machine or apparatus which positions are themselves labeled. If such stored tissue samples are associated with the data structure, an optional ninth data field can be used which comprises a value which links the labeled storage containers with a value in the second data field. Alternatively, the labeled storage containers may be labeled with a value in the second data field.
- the data structure can be associated with labeled storage containers in which one or more samples comprise a component extracted or processed from an excised vascular tissue from a vascular lumen of the patient. Such components include DNA, RNA, cDNA, lipid, carbohydrate, and protein.
- the data structure can optionally comprise a tenth data field in which a value which links the labeled storage containers with a value in the second data field is present.
- labeled storage containers can be labeled with a value in the second data field.
- Catheters can be used to debulk atheroma and other occlusive material from diseased body lumens, and in particular coronary arteries, de novo lesions, and in-stent restenosis lesions. Catheters are also suitable for treating stenoses of body lumens and other hyperplastic and neoplastic conditions in other body lumens, such as the ureter, the biliary duct, respiratory passages, the pancreatic duct, the lymphatic duct, and the like. Neoplastic cell growth will often occur as a result of a tumor surrounding and intruding into a body lumen. Debulking of such material can thus be beneficial to maintain patency of the body lumen.
- the debulked material is typically a continuous strip of tissue removed from the lumen interior wall that ranges from about 1 mg to about 2000 mg; it retains the structure of the tissue prior to removal.
- the continuous strip or strand of tissue removed will typically have a length that is longer than a length of the cutting window.
- the data storage and access structures of the present invention can be applied to a variety of occlusive, stenotic, or hyperplastic material in a variety of body lumens.
- Apparati will generally comprise catheters having catheter bodies adapted for intraluminal introduction to the target body lumen.
- the dimensions and other physical characteristics of the catheter bodies will vary significantly depending on the body lumen which is to be accessed.
- the proximal portions of the catheter bodies will typically be very flexible and suitable for introduction over a guidewire to a target site within the vasculature.
- the smooth muscle cells of the stenotic material show a range of phenotypes, but most of the cells contained myofilaments as well as a relatively high amount of synthetic organelles, such as rough endoplasmic reticulum, Golgi apparatus and mitochondria.
- the material removed from a catheter collection chamber, or a portion thereof, can be placed in a preserving agent, a tissue fixative, and or a preparation agent suitable for a desired test prior to testing the material.
- the material removed from the patient by this method is typically at least one or more continuous strip(s) of material that maintains the structure of the material in vivo.
- the quantity of material removed by the method can be from about 1 mg to about 2000 mg.
- the amount of material is about 1 mg to about 100 mg, about 100 mg to about 200 mg, about 200 mg to about 300 mg, 300 mg to about 400 mg, 400 mg to about 500 mg, 500 mg to about 600 mg, about 600 mg to about 700 mg, 700 mg to about 800 mg, or about 800 mg to about 2000 mg.
- the material can comprise plaque tissue.
- the material can be collected from a single site or at least one additional site in the same or a different body lumen.
- Excised material can be stored to permit later confirmatory or additional testing without having to subject the patient to another percutaneous translumenal lumenectomy procedure.
- the material can be tested by genomic screening, DNA hybridization, RNA hybridization, gene expression analysis, PCR amplification, proteomic testing, drug efficacy screening, presence of one or more protein markers, presence of one or more DNA markers, presence of one or more RNA markers, histological testing, histopathology, cytopathology, cell and tissue type analysis, biopsy, and the like. Additionally, the material can also be cultured and/or tested to determine sensitivity to drugs, toxins, and the like.
- the material can be tested for the presence of DNA, RNA, or protein markers comprising a smooth muscle proliferative promoter, a smooth muscle proliferative inhibitor, a cellular marker, an apoptotic marker, a cell cycle protein, a transcriptional factor, a proliferative marker, an endothelial growth factor, an adhesion molecule, a cytokine, a chemokine, a chemokine receptor, an inflammation marker, a coagulation factor, a fibrinolytic factor, an oxidative stress related molecule, an extracellular matrix molecule, an interleukin, a growth factor, a glycoprotein, a proteoglycan, a cell-surface marker, a serum marker, and or an immune factor, and the like.
- DNA, RNA, or protein markers comprising a smooth muscle proliferative promoter, a smooth muscle proliferative inhibitor, a cellular marker, an apoptotic marker, a cell cycle protein, a transcriptional factor, a
- Tests for each of these molecules and others are well known to the skilled artisan as are methods and preservatives, fixatives and preparation agents for adding to all or a portion of the material collected.
- the results of any of the tests for properties of the removed material can be stored in a data structure according to the invention.
- the material produced by a lumenectomy comprises at least one continuous tissue stand collected in vivo from an inner surface of the body lumen of a subject.
- the body lumen can be an artery or other lumen or vessel of the circulatory system and the material can comprise arterial plaque and associated tissue.
- the continuous strand of tissue provided by the disclosed methods provide a sufficient amount of high quality material to successfully perform at least one or more tests comprising, for example, genomic screening, DNA hybridization, RNA hybridization, gene expression analysis (including serial analysis of gene expression), PCR amplification, proteomic testing, drug efficacy screening, a determination of the presence of one or more protein markers, a determination of the presence of one or more DNA markers, a determination of the presence of one or more RNA markers, histological testing, histopathology, cytopathology, cell type analysis, tissue type analysis, biopsy, and the like. Methods for performing each of the tests are well known to the skilled artisan.
- material collected from a patient can be added to a preserving agent, tissue fixative, or a preparation agent in order to prepare at least a portion of collected material for the desired test.
- Agents known in the art for preserving, fixing or preparing the material for later use include, for example, saline, heparinized saline, liquid nitrogen, formalin, a membrane lysis agent, a RNA or DNA preparation agent, and the like.
- Particular tests that can be carried out successfully on the excised lumenectomy material include, but are not limited to, histology techniques including hematoxylin and eosin staining, connective tissue staining, carbohydrate staining, and lipid staining, and the like.
- tissue array testing enzyme histochemistry, transmission electron microscopy, immunohistology, immunocytochemistry, immunoassays, immunofluorescent assays, immunoprecipitation assays, ELISA, flow cytometry, fluorescent activated cell sorting, radioimmunochemistry, electrophoresis, two-dimensional gel electrophoresis, Western blotting, protein sequencing, mass spectrometry, proteomic analysis, and protein microarray analysis can be carried out.
- cytogenetic testing can be successfully carried out with the lumenectomy materials compositions.
- the compositions can also be prepared for storage for later testing.
- the material collected can be analyzed for the presence of DNA, RNA, or protein markers comprising smooth muscle proliferative promoters (platelet-derived growth factor (PDGF), and PDGF receptor), basic fibroblast growth factor (FGF) and FGF receptor, interleukin 1 (IL-1), or transforming growth factor ⁇ (TGF ⁇ ), and the like), smooth muscle proliferative inhibitors (nitric oxide/endothelial-derived relaxing factors (NO/EDRF), interferon ⁇ (IF ⁇ ), transforming growth factor ⁇ (TGF ⁇ ), or TGF ⁇ receptor, and the like), cellular markers (including CD68, CD3, CD4, CD8, CD20, smooth muscle actin, or CD31, and the like), apoptotic markers (Bcl-x, Bcl-2, Bax, Bak, or P53, and the like), cell cycle proteins (cyclin A, cyclin B, cyclin D, or cyclin E, and the like), transcriptional factors (transcription factor NF ⁇ B, transcription factor E2F, transcription
- Analysis of the excised material by any of the above tests can be used for diagnosis of a condition in a patient, to design a treatment directive or protocol for a subject, to monitor progress of a treatment regimen, or if tests from a number of individuals are compared, the information can be used in a multi-patient analysis, such as a cardiovascular disease population study.
Abstract
Material removed by a debulking catheter from a body lumen can be preserved. Materials can be collected from many different patients and/or from multiple procedures on individual patients. Data which describe the properties or qualities of the removed material and/or the patient and/or the patient's family or environment can be stored on computer readable media. The stored data can be used to draw correlations, to stratify groups of patients, to provide risk assessments, to provide diagnoses and/or prognoses. Further tests can be done on the stored materials at later times after the procedures have been completed.
Description
- The present application is a continuation-in-part of U.S. patent application Ser. No. 11/108,887, filed Apr. 19, 2005. The complete disclosure of which is incorporated herein by reference.
- The present invention relates generally to computer readable media for storing data relating to patients and tissue samples excised from their vascular or other lumens. The data may be used to analyze current, past, or future patient health, to assess treatments, to evaluate drugs, to evaluate risk factors, and to determine proposed treatments or assessments.
- Cardiovascular disease frequently arises from the accumulation of atheromatous material on the inner walls of vascular lumens, particularly arterial lumens of the coronary and other vasculature, resulting in a condition known as atherosclerosis. Atherosclerosis occurs naturally as a result of aging, but may also be aggravated by factors such as diet, hypertension, heredity, vascular injury, and the like. Atheromatous and other vascular deposits restrict blood flow and can cause ischemia which, in acute cases, can result in myocardial infarction. Atheromatous deposits can have widely varying properties, with some deposits being relatively soft and others being fibrous and/or calcified. In the latter case, the deposits are frequently referred to as plaque.
- One conventional treatment for cardiovascular disease is the use of stents. Endoluminal stents are commonly used to treat obstructed or weakened body lumens, such as blood vessels and other vascular lumens. Once deployed in the blood vessel, the stent can remain in the body lumen where it will maintain the patency of the lumen and/or support the walls of the lumen which surround it. One factor impeding the success of stent technology in endoluminal treatments is the frequent occurrence of in-stent restenosis, characterized by proliferation and migration of smooth muscle cells within and/or adjacent to the implanted stent, causing reclosure or blockage of the body lumen.
- Atherosclerosis and restenosis can be treated in a variety of ways, including drugs, bypass surgery, and a variety of catheter-based approaches which rely on intravascular debulking or removal of the atheromatous or other material occluding a blood vessel. Of particular interest to the present invention, a variety of methods for cutting or dislodging material and removing such material from the blood vessel have been proposed, generally being referred to as atherectomy procedures. Atherectomy catheters intended to excise material from the blood vessel lumen generally employ a rotatable and/or axially translatable cutting blade which can be advanced into or past the occlusive material in, order to cut and separate such material from the blood vessel lumen.
- There is a need in the art for methods and tools for managing and storing materials removed from body lumens. There is a need in the art for methods and tools for managing and storing information related to and/or derived from materials removed from body lumens.
- One aspect of the invention provides one or more computer readable media having a data structure stored thereon. The data structure comprises a first data field comprising a value corresponding to a property of a first tissue sample excised from a vascular lumen of a patient and a second data field comprising data identifying the patient. Optional additional data fields include a third data field comprising a value corresponding to cardiac health of the patient, a fourth data field comprising a value corresponding to a characteristic of the patient's blood, a fifth data field comprising a value corresponding to family history of the patient, a sixth data field comprising a value corresponding to the patient's medical history, a seventh data field comprising a value corresponding to a property of a second tissue sample excised from a vascular lumen of the patient at a distinct time, an eighth data field comprising a value corresponding to a property of a second tissue sample excised from distinct vascular lumen of the patient on the same day as the first tissue sample, a ninth data field which comprises a value which links a labeled storage container comprising excised tissue with a value in the second data field, a tenth data field which comprises a value which links the labeled storage containers comprising a component extracted or processed from an extracted tissue with a value in the second data field. These can be used separately or cumulatively. These data fields are not an exclusive list of possible useful data fields.
- For a further understanding of the nature and advantages of the invention, reference should be made to the following description taken in conjunction with the accompanying drawings.
-
FIG. 1 shows relevant markers for which the excised vascular material can be tested for expression, and about which data can be stored. - Data collected related to samples of materials removed from body lumens can be stored in data structures. The stored data can be used to draw correlations, to stratify groups of patients, to provide risk assessments, to provide diagnoses and/or prognoses. Libraries of samples can be assembled to be used for studies of drugs, candidate drugs, toxins, therapeutic treatments, etc. The samples can be preserved according to any method known in the art. Samples may be frozen, for example, in liquid nitrogen. They may be preserved in paraffin, dried, freeze dried, etc. Samples may be treated to achieve a purified or semi-purified component of the sample. Samples may be treated, for example to extract DNA or protein. Samples may be treated to extract mRNA and to preserve it or “convert” it to cDNA. Desirably, samples are stored in a consistent and systematic way so that patient information remains associated with the samples so that patient outcome or other data collected at a later time can be associated with the sample concurrently or at a later time.
- Samples within a library can be stored and associated with information related to the sample itself, e.g., its properties, and the patient from whom the sample was excised. Other information that can be associated with the sample include results of analyses of the sample, patient history information, patient outcome information, drug efficacy information, therapeutic efficacy information, family history, factors of the patient related to cardiac disease, factors of the patient related to non-cardiac disease. In some cases this information may be stored without association with the physical samples. Patient identifying information may be coded so that confidentiality can be maintained while still permitting correlation of various patient attributes with the samples.
- One or more aspects of the invention may be embodied in computer-usable data and computer-executable instructions, such as in one or more program modules, executed by one or more computers or other devices. Generally, program modules include routines, programs, objects, components, data structures, etc. that perform particular tasks or implement particular abstract data types when executed by a processor in a computer or other device. The computer executable instructions may be stored on a computer readable medium such as a hard disk, optical disk, removable storage media, solid state memory, RAM, etc. As will be appreciated by one of skill in the art, the functionality of the program modules may be combined or distributed as desired in various catheters. In addition, the functionality may be embodied in whole or in part in firmware or hardware equivalents such as integrated circuits, field programmable gate arrays (FPGA), and the like. Particular data structures may be used to more effectively implement one or more aspects of the invention, and such data structures are contemplated within the scope of computer executable instructions and computer-usable data described herein.
- Data fields which are present in the data structures of the present invention may include one or more of those discussed below. A first data field comprises a value corresponding to a property of a first tissue sample excised from a vascular lumen of a patient. The tissue sample is typically material that has been excised from a body lumen. The body lumen is often a vascular lumen. The property may be, for example, level of a marker in the tissue, composition of the tissue sample, histologic characterization, immunochemical characterization of the tissue, a genomic characteristic of the tissue, level of a mRNA in the tissue, location of the vascular lumen from which the tissue was excised, or volume or mass of the excised tissue. Any property of the tissue may be stored in this data field. A second data field may comprise data identifying a patient. The patient data may be anonymous or identify a person. If anonymous, the code will uniquely identify a patient's characteristics, without actually identifying the patient. Thus data can be used for studies, without divulging identities of the patients.
- An optional third data field comprises a value corresponding to cardiac health of the patient. Such values may, for example, relate to past infarct history, past angioplasty procedures, or past cholesterol values. A possible fourth data field comprises a value corresponding to a characteristic of the patient's blood. The blood may have been withdrawn at the time of or before tissue excision. The blood characteristic may be any known in the art, including but not limited to, sedimentation rate, red blood cell count, white blood'cell count, triglycerides, and C-reactive protein.
- An optional fifth data field comprises a value corresponding to family history of the patient. Thus a value can be assigned to family history events based on degree of relatedness of the family member and the severity of the event. An optional sixth data field comprises a value corresponding to the patient's own medical history. This history includes but is not limited to cardiac related events. Thus other medical history events can be recorded which may not be currently known to be associated with vascular occlusion, but which may in fact have a correlation. Such data will make the data structure useful for discovering new associations, risks, and mechanisms. Such data may also be useful in stratifying patients for treatment regimens and for drug trials.
- An optional seventh data field comprises a value corresponding to a property of a second tissue sample excised from a vascular lumen of the patient at a distinct time from the first tissue sample. The second tissue sample can be excised from the same vascular lumen as the first tissue sample or from a different vascular lumen of the patient. An optional eighth data field comprises a value corresponding to a property of a second tissue sample excised from a distinct vascular lumen of the patient on the same day as the first tissue sample.
- The computer readable media can optionally be associated with one or more excised tissue samples in labeled storage containers. Labeled storage containers includes storage containers that are in fixed positions or parts of a machine or apparatus which positions are themselves labeled. If such stored tissue samples are associated with the data structure, an optional ninth data field can be used which comprises a value which links the labeled storage containers with a value in the second data field. Alternatively, the labeled storage containers may be labeled with a value in the second data field. Alternatively or optionally the data structure can be associated with labeled storage containers in which one or more samples comprise a component extracted or processed from an excised vascular tissue from a vascular lumen of the patient. Such components include DNA, RNA, cDNA, lipid, carbohydrate, and protein. In such a case, the data structure can optionally comprise a tenth data field in which a value which links the labeled storage containers with a value in the second data field is present. Alternatively, such labeled storage containers can be labeled with a value in the second data field. There is no significance to the numbers of the data fields as used herein. Data fields with sequential numbers need not be used. Thus, for example, a structure can comprise data fields with
fields data fields - Catheters can be used to debulk atheroma and other occlusive material from diseased body lumens, and in particular coronary arteries, de novo lesions, and in-stent restenosis lesions. Catheters are also suitable for treating stenoses of body lumens and other hyperplastic and neoplastic conditions in other body lumens, such as the ureter, the biliary duct, respiratory passages, the pancreatic duct, the lymphatic duct, and the like. Neoplastic cell growth will often occur as a result of a tumor surrounding and intruding into a body lumen. Debulking of such material can thus be beneficial to maintain patency of the body lumen. The debulked material is typically a continuous strip of tissue removed from the lumen interior wall that ranges from about 1 mg to about 2000 mg; it retains the structure of the tissue prior to removal. The continuous strip or strand of tissue removed will typically have a length that is longer than a length of the cutting window. The data storage and access structures of the present invention can be applied to a variety of occlusive, stenotic, or hyperplastic material in a variety of body lumens.
- Apparati will generally comprise catheters having catheter bodies adapted for intraluminal introduction to the target body lumen. The dimensions and other physical characteristics of the catheter bodies will vary significantly depending on the body lumen which is to be accessed. In the exemplary case of atherectomy catheters intended for intravascular introduction, the proximal portions of the catheter bodies will typically be very flexible and suitable for introduction over a guidewire to a target site within the vasculature.
- Generally, the smooth muscle cells of the stenotic material show a range of phenotypes, but most of the cells contained myofilaments as well as a relatively high amount of synthetic organelles, such as rough endoplasmic reticulum, Golgi apparatus and mitochondria. One can determine how much stenotic tissue is retrieved in an access procedure. One can determine presence or absence of inflammatory cells in excised tissue. One can determine the presence of inflammatory cells within critical areas of plaque. Determination of the location and degree of inflammatory cells present may facilitate a more informed characterization or diagnosis.
- The material removed from a catheter collection chamber, or a portion thereof, can be placed in a preserving agent, a tissue fixative, and or a preparation agent suitable for a desired test prior to testing the material. The material removed from the patient by this method is typically at least one or more continuous strip(s) of material that maintains the structure of the material in vivo. The quantity of material removed by the method can be from about 1 mg to about 2000 mg. Typically the amount of material is about 1 mg to about 100 mg, about 100 mg to about 200 mg, about 200 mg to about 300 mg, 300 mg to about 400 mg, 400 mg to about 500 mg, 500 mg to about 600 mg, about 600 mg to about 700 mg, 700 mg to about 800 mg, or about 800 mg to about 2000 mg. In a typical procedure about 400 mg to about 600 mg of material is removed and available for testing and/or storage. Collection of one or more continuous strips of material from the inner surface of a lumen may be longer than a largest dimension of the cutting window of a catheter used to remove the material. In a particular example, the material can comprise plaque tissue. The material can be collected from a single site or at least one additional site in the same or a different body lumen.
- Excised material can be stored to permit later confirmatory or additional testing without having to subject the patient to another percutaneous translumenal lumenectomy procedure. The material can be tested by genomic screening, DNA hybridization, RNA hybridization, gene expression analysis, PCR amplification, proteomic testing, drug efficacy screening, presence of one or more protein markers, presence of one or more DNA markers, presence of one or more RNA markers, histological testing, histopathology, cytopathology, cell and tissue type analysis, biopsy, and the like. Additionally, the material can also be cultured and/or tested to determine sensitivity to drugs, toxins, and the like. The material can be tested for the presence of DNA, RNA, or protein markers comprising a smooth muscle proliferative promoter, a smooth muscle proliferative inhibitor, a cellular marker, an apoptotic marker, a cell cycle protein, a transcriptional factor, a proliferative marker, an endothelial growth factor, an adhesion molecule, a cytokine, a chemokine, a chemokine receptor, an inflammation marker, a coagulation factor, a fibrinolytic factor, an oxidative stress related molecule, an extracellular matrix molecule, an interleukin, a growth factor, a glycoprotein, a proteoglycan, a cell-surface marker, a serum marker, and or an immune factor, and the like. Tests for each of these molecules and others are well known to the skilled artisan as are methods and preservatives, fixatives and preparation agents for adding to all or a portion of the material collected. The results of any of the tests for properties of the removed material can be stored in a data structure according to the invention.
- The material produced by a lumenectomy comprises at least one continuous tissue stand collected in vivo from an inner surface of the body lumen of a subject. The body lumen can be an artery or other lumen or vessel of the circulatory system and the material can comprise arterial plaque and associated tissue. The continuous strand of tissue provided by the disclosed methods provide a sufficient amount of high quality material to successfully perform at least one or more tests comprising, for example, genomic screening, DNA hybridization, RNA hybridization, gene expression analysis (including serial analysis of gene expression), PCR amplification, proteomic testing, drug efficacy screening, a determination of the presence of one or more protein markers, a determination of the presence of one or more DNA markers, a determination of the presence of one or more RNA markers, histological testing, histopathology, cytopathology, cell type analysis, tissue type analysis, biopsy, and the like. Methods for performing each of the tests are well known to the skilled artisan. It is also well known that material collected from a patient can be added to a preserving agent, tissue fixative, or a preparation agent in order to prepare at least a portion of collected material for the desired test. Agents known in the art for preserving, fixing or preparing the material for later use include, for example, saline, heparinized saline, liquid nitrogen, formalin, a membrane lysis agent, a RNA or DNA preparation agent, and the like. Particular tests that can be carried out successfully on the excised lumenectomy material include, but are not limited to, histology techniques including hematoxylin and eosin staining, connective tissue staining, carbohydrate staining, and lipid staining, and the like. In addition, tissue array testing, enzyme histochemistry, transmission electron microscopy, immunohistology, immunocytochemistry, immunoassays, immunofluorescent assays, immunoprecipitation assays, ELISA, flow cytometry, fluorescent activated cell sorting, radioimmunochemistry, electrophoresis, two-dimensional gel electrophoresis, Western blotting, protein sequencing, mass spectrometry, proteomic analysis, and protein microarray analysis can be carried out. Further, cytogenetic testing, Nothern blotting, RNase protection assays, in situ hybridization assays, DNA microarray testing, reverse transcription polymerase chain reaction PCR (RT-PCR), Southern blotting, DNA sequencing, PCR amplification, single strand conformational polymorphism assays, single strand polymorphism (SNP) assays, and serial analysis of gene expression (SAGE) assays can be successfully carried out with the lumenectomy materials compositions. The compositions can also be prepared for storage for later testing.
- The material collected can be analyzed for the presence of DNA, RNA, or protein markers comprising smooth muscle proliferative promoters (platelet-derived growth factor (PDGF), and PDGF receptor), basic fibroblast growth factor (FGF) and FGF receptor, interleukin 1 (IL-1), or transforming growth factor α (TGFα), and the like), smooth muscle proliferative inhibitors (nitric oxide/endothelial-derived relaxing factors (NO/EDRF), interferon γ (IFγ), transforming growth factor β (TGFβ), or TGFβ receptor, and the like), cellular markers (including CD68, CD3, CD4, CD8, CD20, smooth muscle actin, or CD31, and the like), apoptotic markers (Bcl-x, Bcl-2, Bax, Bak, or P53, and the like), cell cycle proteins (cyclin A, cyclin B, cyclin D, or cyclin E, and the like), transcriptional factors (transcription factor NFκB, transcription factor E2F, transcription factor CREB, or transcription factor KLF5/BTEB2, and the like), proliferative markers (Ki-67 or proliferating cell nuclear antigen (PCNA), and the like), endothelial growth factors (vascular endothelial growth factor (VEGF), and the like), adhesion molecules (intercellular adhesion molecule-1 (ICAM-1), CD11a/CD18 (LFA-1), CD11b/CD18 (MAC-1), vascular cell adhesion molecule-1 (VCAM-1), p-selectin (CD62P), or integrin, and the like), cytokines (interleukin 6 (IL-6) or interleukin 8 (IL-8), and the like), chemokines and chemokine receptors (monocyte chemoattractant protein 1 (MCP-1) and its receptor CCR2, CX3C chemokine fractalkine and its receptor CX3CR1, or eotaxin and its receptor CCR3, and the like), inflammation markers (C-reactive protein, myeloperoxidase, or complement proteins, and the like), coagulation factors and fibrinolytic factors (fibrinogen, prothrombinogen, plasminogen activator, tissue factor, or glycoprotein receptor on platelets (GpIIb-IIIa), and the like), oxidative stress related molecules (oxidized LDL and its receptor CD36, or lipoxygenase, and the like), extracellular matrix molecules (collagen, matrix metalloproteinase (MMP), FK506-binding protein 12 (FKBP12), endothelial differentiation gene receptors (EDG receptors), ephrins, elastin, lamin receptor, monocyte colony stimulating factor (M-CSF), tumor necrosis factor (TNF), or PDZ domain proteins, and the like), interleukins (interleukin 1 (IL-1), interleukin 6 (IL-6), or interleukin 8 (IL-8), and the like), growth factors (platelet-derived frowth factor (PDGF), basic fibroblast growth factor (FGF), transforming growth factor α (TGFα), or transforming growth factor β (TGFβ), and the like), glycoproteins, proteoglycans (versican, hyluronan, biglycan, or deorin, and the like), cell-surface markers, serum markers, and/or immune factors (stromal cell-derived factor 1a (SDP-1)), and the like). Analysis of the excised material by any of the above tests can be used for diagnosis of a condition in a patient, to design a treatment directive or protocol for a subject, to monitor progress of a treatment regimen, or if tests from a number of individuals are compared, the information can be used in a multi-patient analysis, such as a cardiovascular disease population study.
- While all the above is a complete description of the preferred embodiments of the inventions, various alternatives, modifications, and equivalents may be used. Therefore, although the foregoing invention has been described in detail for purposes of clarity of understanding, it will be obvious that certain modifications may be practiced within the scope of the appended claims.
Claims (21)
1. An article of manufacture, said article comprising:
a computer readable media having computer executable instructions stored thereon, which when executed by a computer causes the computer to perform an operation comprising:
receiving a set of data fields derived from a patient sample, wherein the set of data fields comprise:
a first value corresponding to a property of a first tissue sample comprising tissue excised from an inner surface of a vascular lumen of a patient, and
a second value corresponding to data identifying the patient;
storing the of set of data fields;
correlating the first and second values; and
diagnosing the patient.
2. The computer readable media of claim 1 further comprising: a third data field comprising a value corresponding to cardiac health of the patient.
3. The computer readable media of claim 1 wherein the property is a level of a marker in the tissue.
4. The computer readable media of claim 1 wherein the property is composition of the tissue sample.
5. The computer readable media of claim 1 wherein the property is histologic characterization of the tissue.
6. The computer readable media of claim 1 wherein the property is an immunochemical characterization of the tissue.
7. The computer readable media of claim 1 wherein the property is a genomic characteristic.
8. The computer readable media of claim 1 wherein the property is level of a mRNA.
9. The computer readable media of claim 1 wherein the property is location of the vascular lumen from which the tissue was excised.
10. The computer readable media of claim 1 wherein the property is volume or mass of the excised tissue.
11. The computer readable media of claim 1 further comprising: a fourth data field comprising a value corresponding to a characteristic of the patient's blood.
12. The computer readable media of claim 11 wherein the patient's blood was withdrawn at the time of or before tissue excision.
13. The computer readable media of claim 1 further comprising: a fifth data field comprising a value corresponding to family history of the patient.
14. The computer readable media of claim 1 further comprising: a sixth data field comprising a value corresponding to the patient's medical history.
15. The computer readable media of claim 1 further comprising: a seventh data field comprising a value corresponding to a property of a second tissue sample excised from a vascular lumen of the patient at a distinct time.
16. The computer readable media of claim 15 wherein the second tissue sample is excised from the same vascular lumen as the first tissue sample.
17. The computer readable media of claim 1 further comprising: an eighth data field comprising a value corresponding to a property of a second tissue sample excised from distinct vascular lumen of the patient on the same day as the first tissue sample.
18. The computer readable media of claim 1 wherein said media are associated with one or more excised tissue samples in labeled storage containers, wherein the computer readable media comprise a ninth data field which comprises a value which links the labeled storage containers with a value in the second data field.
19. The computer readable media of claim 1 wherein said media are associated with one or more excised tissue samples in labeled storage containers, wherein the storage containers are labeled with a value in the second data field.
20. The computer readable media of claim 1 wherein said media are associated with one or more samples in labeled storage containers, wherein the one or more samples comprise a component extracted or processed from an excised vascular tissue from a vascular lumen of the patient, wherein the component is selected from the group consisting of DNA, RNA, cDNA, and protein, and wherein the computer readable media comprise a tenth data field which comprises a value which links the labeled storage containers with a value in the second data field.
21. The computer readable media of claim 1 wherein said media are associated with one or more samples in labeled storage containers, wherein the storage containers are labeled with a value in the second data field, wherein the samples comprise a component extracted or processed from an excised vascular tissue from a vascular lumen of the patient, wherein the component is selected from the group consisting of DNA, RNA, cDNA, and protein.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/880,010 US20110060606A1 (en) | 2005-04-19 | 2010-09-10 | Libraries and data structures of materials removed by debulking catheters |
US13/609,537 US20130013216A1 (en) | 2005-04-19 | 2012-09-11 | Libraries and data structures of materials removed by debulking catheters |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/108,887 US20050222519A1 (en) | 2000-12-20 | 2005-04-19 | Debulking catheters and methods |
US11/230,924 US7794413B2 (en) | 2005-04-19 | 2005-09-21 | Libraries and data structures of materials removed by debulking catheters |
US12/880,010 US20110060606A1 (en) | 2005-04-19 | 2010-09-10 | Libraries and data structures of materials removed by debulking catheters |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/230,924 Continuation US7794413B2 (en) | 2005-04-19 | 2005-09-21 | Libraries and data structures of materials removed by debulking catheters |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/609,537 Continuation US20130013216A1 (en) | 2005-04-19 | 2012-09-11 | Libraries and data structures of materials removed by debulking catheters |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110060606A1 true US20110060606A1 (en) | 2011-03-10 |
Family
ID=37889556
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/230,924 Expired - Fee Related US7794413B2 (en) | 2005-04-19 | 2005-09-21 | Libraries and data structures of materials removed by debulking catheters |
US12/880,010 Abandoned US20110060606A1 (en) | 2005-04-19 | 2010-09-10 | Libraries and data structures of materials removed by debulking catheters |
US13/609,537 Abandoned US20130013216A1 (en) | 2005-04-19 | 2012-09-11 | Libraries and data structures of materials removed by debulking catheters |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/230,924 Expired - Fee Related US7794413B2 (en) | 2005-04-19 | 2005-09-21 | Libraries and data structures of materials removed by debulking catheters |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/609,537 Abandoned US20130013216A1 (en) | 2005-04-19 | 2012-09-11 | Libraries and data structures of materials removed by debulking catheters |
Country Status (4)
Country | Link |
---|---|
US (3) | US7794413B2 (en) |
EP (1) | EP1938196A4 (en) |
CA (1) | CA2622716A1 (en) |
WO (1) | WO2007035909A2 (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7927784B2 (en) | 2000-12-20 | 2011-04-19 | Ev3 | Vascular lumen debulking catheters and methods |
US7794413B2 (en) * | 2005-04-19 | 2010-09-14 | Ev3, Inc. | Libraries and data structures of materials removed by debulking catheters |
US7989207B2 (en) * | 2006-02-17 | 2011-08-02 | Tyco Healthcare Group Lp | Testing lumenectomy samples for markers of non-vascular diseases |
US8784654B2 (en) * | 2007-11-14 | 2014-07-22 | Bayer Medical Care, Inc. | Methods and systems for biological sample collection and analysis |
US9125562B2 (en) | 2009-07-01 | 2015-09-08 | Avinger, Inc. | Catheter-based off-axis optical coherence tomography imaging system |
US8062316B2 (en) | 2008-04-23 | 2011-11-22 | Avinger, Inc. | Catheter system and method for boring through blocked vascular passages |
US8548571B2 (en) | 2009-12-08 | 2013-10-01 | Avinger, Inc. | Devices and methods for predicting and preventing restenosis |
US20100125253A1 (en) * | 2008-11-17 | 2010-05-20 | Avinger | Dual-tip Catheter System for Boring through Blocked Vascular Passages |
WO2010129075A1 (en) | 2009-04-28 | 2010-11-11 | Avinger, Inc. | Guidewire support catheter |
CA2763324C (en) | 2009-05-28 | 2018-10-23 | Avinger, Inc. | Optical coherence tomography for biological imaging |
EP2448502B1 (en) | 2009-07-01 | 2022-04-06 | Avinger, Inc. | Atherectomy catheter with laterally-displaceable tip |
US11382653B2 (en) | 2010-07-01 | 2022-07-12 | Avinger, Inc. | Atherectomy catheter |
JP2013531542A (en) | 2010-07-01 | 2013-08-08 | アビンガー・インコーポレイテッド | An atherectomy catheter having a longitudinally movable drive shaft |
WO2014039096A1 (en) | 2012-09-06 | 2014-03-13 | Avinger, Inc. | Re-entry stylet for catheter |
WO2014039099A1 (en) | 2012-09-06 | 2014-03-13 | Avinger, Inc. | Balloon atherectomy catheters with imaging |
US9949754B2 (en) | 2011-03-28 | 2018-04-24 | Avinger, Inc. | Occlusion-crossing devices |
WO2012145133A2 (en) | 2011-03-28 | 2012-10-26 | Avinger, Inc. | Occlusion-crossing devices, imaging, and atherectomy devices |
WO2013059363A1 (en) | 2011-10-17 | 2013-04-25 | Avinger, Inc. | Atherectomy catheters and non-contact actuation mechanism for catheters |
US9345406B2 (en) | 2011-11-11 | 2016-05-24 | Avinger, Inc. | Occlusion-crossing devices, atherectomy devices, and imaging |
US8906613B2 (en) * | 2012-02-14 | 2014-12-09 | Lasse Folkersen | Method and kit for performing profiling of endarterectomy patients |
EP2849636B1 (en) | 2012-05-14 | 2020-04-22 | Avinger, Inc. | Optical coherence tomography with graded index fiber for biological imaging |
EP2849661B1 (en) | 2012-05-14 | 2020-12-09 | Avinger, Inc. | Atherectomy catheters with imaging |
EP2849660B1 (en) | 2012-05-14 | 2021-08-25 | Avinger, Inc. | Atherectomy catheter drive assemblies |
US11284916B2 (en) | 2012-09-06 | 2022-03-29 | Avinger, Inc. | Atherectomy catheters and occlusion crossing devices |
US9498247B2 (en) | 2014-02-06 | 2016-11-22 | Avinger, Inc. | Atherectomy catheters and occlusion crossing devices |
US11096717B2 (en) | 2013-03-15 | 2021-08-24 | Avinger, Inc. | Tissue collection device for catheter |
WO2014143064A1 (en) | 2013-03-15 | 2014-09-18 | Avinger, Inc. | Chronic total occlusion crossing devices with imaging |
US10932670B2 (en) | 2013-03-15 | 2021-03-02 | Avinger, Inc. | Optical pressure sensor assembly |
EP3019096B1 (en) | 2013-07-08 | 2023-07-05 | Avinger, Inc. | System for identification of elastic lamina to guide interventional therapy |
CN106102608B (en) | 2014-02-06 | 2020-03-24 | 阿维格公司 | Atherectomy catheters and occlusion crossing devices |
EP3166512B1 (en) | 2014-07-08 | 2020-08-19 | Avinger, Inc. | High speed chronic total occlusion crossing devices |
US10568520B2 (en) | 2015-07-13 | 2020-02-25 | Avinger, Inc. | Micro-molded anamorphic reflector lens for image guided therapeutic/diagnostic catheters |
EP3407777B1 (en) | 2016-01-25 | 2020-12-30 | Avinger, Inc. | Oct imaging catheter with lag correction |
CN108882948A (en) | 2016-04-01 | 2018-11-23 | 阿维格公司 | Rotary-cut art conduit with zigzag cutter |
WO2017210466A1 (en) | 2016-06-03 | 2017-12-07 | Avinger, Inc. | Catheter device with detachable distal end |
CN109414273B (en) | 2016-06-30 | 2023-02-17 | 阿维格公司 | Atherectomy catheter with shapeable distal tip |
EP4044942A4 (en) | 2019-10-18 | 2023-11-15 | Avinger, Inc. | Occlusion-crossing devices |
Citations (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4646736A (en) * | 1984-09-10 | 1987-03-03 | E. R. Squibb & Sons, Inc. | Transluminal thrombectomy apparatus |
US5226910A (en) * | 1989-07-05 | 1993-07-13 | Kabushiki Kaisha Topcon | Surgical cutter |
US5306244A (en) * | 1984-05-14 | 1994-04-26 | Surgical Systems & Instruments, Inc. | Method of guidewire insertion |
US5336616A (en) * | 1990-09-12 | 1994-08-09 | Lifecell Corporation | Method for processing and preserving collagen-based tissues for transplantation |
US5376632A (en) * | 1990-01-29 | 1994-12-27 | Konings; Frank J. | Cyclodextrin based erythropoietin formulation |
US5406959A (en) * | 1992-06-22 | 1995-04-18 | Mann; David | Method and apparatus for obtaining an arterial biopsy and for diagnosting diseases of the vascular system |
US5535756A (en) * | 1994-01-06 | 1996-07-16 | Parasher; Vinod K. | Catheter with simultaneous brush cytology and scrape biopsy capability |
US5538504A (en) * | 1992-07-14 | 1996-07-23 | Scimed Life Systems, Inc. | Intra-extravascular drug delivery catheter and method |
US5571122A (en) * | 1992-11-09 | 1996-11-05 | Endovascular Instruments, Inc. | Unitary removal of plaque |
US5580722A (en) * | 1989-07-18 | 1996-12-03 | Oncogene Science, Inc. | Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease |
US5595722A (en) * | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
US5626562A (en) * | 1994-11-28 | 1997-05-06 | Devices For Vascular Intervention | Drug delivery catheter |
US5731489A (en) * | 1991-08-14 | 1998-03-24 | Detlev Ganten | Transgenic rats containing at least one human gene which participates in blood pressure control |
US5796861A (en) * | 1996-07-12 | 1998-08-18 | Frim International, Inc. | Mosaic construction, processing, and review of very large electronic micrograph composites |
US5803078A (en) * | 1994-05-06 | 1998-09-08 | Brauner; Mark E. | Methods and apparatus for intrapulmonary therapy and drug administration |
US5843000A (en) * | 1996-05-07 | 1998-12-01 | The General Hospital Corporation | Optical biopsy forceps and method of diagnosing tissue |
US5941869A (en) * | 1997-02-12 | 1999-08-24 | Prolifix Medical, Inc. | Apparatus and method for controlled removal of stenotic material from stents |
US6017960A (en) * | 1992-03-31 | 2000-01-25 | Regents Of The University Of Michigan | Method of treating post-inflammatory hyperpigmentation in black skin with a retinoid, and method of lightening black skin with a retinoid |
US6068638A (en) * | 1995-10-13 | 2000-05-30 | Transvascular, Inc. | Device, system and method for interstitial transvascular intervention |
US20010007083A1 (en) * | 1999-12-29 | 2001-07-05 | Roorda Wouter E. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
US6283983B1 (en) * | 1995-10-13 | 2001-09-04 | Transvascular, Inc. | Percutaneous in-situ coronary bypass method and apparatus |
US6353757B2 (en) * | 1999-05-07 | 2002-03-05 | Cedars-Sinai Medical Center | Method for collecting data pertinent to predictors of heart arrhythmias using an animal test subject |
US6355451B1 (en) * | 1996-11-27 | 2002-03-12 | Boston Heart Foundation, Inc. | Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
US20020072484A1 (en) * | 2000-09-20 | 2002-06-13 | Alters Susan E. | Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders |
US6419625B1 (en) * | 1997-01-03 | 2002-07-16 | Robin G. Smith | Methods and devices for ex vivo irradiation of autologous coronary bypass conduit |
US6423742B1 (en) * | 1999-09-02 | 2002-07-23 | Drake Larson | Compositions for reducing vascular plaque formation and methods of using same |
US20030032936A1 (en) * | 2001-08-10 | 2003-02-13 | Lederman Robert J. | Side-exit catheter and method for its use |
US6524795B1 (en) * | 1997-03-10 | 2003-02-25 | Interleukin Genetics, Inc. | Diagnostics for cardiovascular disorders |
US6534322B1 (en) * | 1997-06-10 | 2003-03-18 | Medlyte Diagnostics, Inc. | Kits for early detection of heart disease |
US20030064522A1 (en) * | 2001-09-14 | 2003-04-03 | Alan Kleinfeld | Diagnostic markers for ischemia |
US6544276B1 (en) * | 1996-05-20 | 2003-04-08 | Medtronic Ave. Inc. | Exchange method for emboli containment |
US20030100486A1 (en) * | 2000-12-14 | 2003-05-29 | Ridker Paul M. | Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes |
US20030125758A1 (en) * | 2000-12-20 | 2003-07-03 | Fox Hollow Technologies, Inc. | Debulking catheters and methods |
US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
US20030219813A1 (en) * | 2002-04-05 | 2003-11-27 | Millennium Pharmaceuticals, Inc. | Identification of a family of secreted proteins in vascular endothelium |
US20040014198A1 (en) * | 2002-05-23 | 2004-01-22 | Craft David L. | Non-revertible beta-oxidation blocked candida tropicalis |
US20040030320A1 (en) * | 1999-06-02 | 2004-02-12 | Boston Scientific Corporation | Devices and methods for delivering a drug |
US20040110241A1 (en) * | 2002-12-06 | 2004-06-10 | Segal Mark S. | Materials and methods for monitoring vascular endothelial function |
US20040209307A1 (en) * | 2001-08-20 | 2004-10-21 | Biosite Incorporated | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20050064516A1 (en) * | 2003-09-18 | 2005-03-24 | Kantor Aaron B. | Biological markers for diagnosing multiple sclerosis |
US6904434B1 (en) * | 2001-12-18 | 2005-06-07 | Siebel Systems, Inc. | Method and system for providing real-time clinical trial enrollment data |
US20050222519A1 (en) * | 2000-12-20 | 2005-10-06 | Fox Hollow Technologies, Inc. | Debulking catheters and methods |
US6962776B2 (en) * | 2001-02-23 | 2005-11-08 | Mayo Foundation For Medical Education And Research | Methods and materials for evaluating cardiovascular conditions |
US20060024323A1 (en) * | 1994-02-09 | 2006-02-02 | Epitopix, Llc | Active immunization using a siderophore receptor protein |
US20060024234A1 (en) * | 2000-06-02 | 2006-02-02 | Large Scale Proteomics Corporation, A Division Of Large Scale Biology Corporation | Protein markers for pharmaceuticals and related toxicity |
US20060236019A1 (en) * | 2005-04-19 | 2006-10-19 | Fox Hollow Technologies, Inc. | Libraries and data structures of materials removed by debulking catheters |
US20060239982A1 (en) * | 2000-12-20 | 2006-10-26 | Fox Hollow Technologies, Inc. | Debulking catheters and methods |
US20070173901A1 (en) * | 2006-01-24 | 2007-07-26 | Reeve Helen L | Method and device for detecting and treating depression |
US20070218519A1 (en) * | 2005-10-11 | 2007-09-20 | Tethys Bioscience, Inc. | Diabetes-associated markers and methods of use thereof |
US7989207B2 (en) * | 2006-02-17 | 2011-08-02 | Tyco Healthcare Group Lp | Testing lumenectomy samples for markers of non-vascular diseases |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US540334A (en) * | 1895-06-04 | Mangle | ||
US2178790A (en) | 1938-05-07 | 1939-11-07 | Abner E Henry | Cutting implement |
ES152231Y (en) | 1969-10-02 | 1970-07-01 | Ballestero Sierra | A PERFECTED TROCAR. |
US3815604A (en) | 1972-06-19 | 1974-06-11 | Malley C O | Apparatus for intraocular surgery |
US3831006A (en) | 1973-01-19 | 1974-08-20 | Honeywell Inc | Patient-specimen identification system using stored associated numbers |
US3837345A (en) | 1973-08-31 | 1974-09-24 | A Matar | Venous valve snipper |
US3995619A (en) | 1975-10-14 | 1976-12-07 | Glatzer Stephen G | Combination subcutaneous suture remover, biopsy sampler and syringe |
US4210146A (en) | 1978-06-01 | 1980-07-01 | Anton Banko | Surgical instrument with flexible blade |
US5024651A (en) | 1984-05-14 | 1991-06-18 | Surgical Systems & Instruments, Inc. | Atherectomy system with a sleeve |
US4926858A (en) | 1984-05-30 | 1990-05-22 | Devices For Vascular Intervention, Inc. | Atherectomy device for severe occlusions |
US4781186A (en) | 1984-05-30 | 1988-11-01 | Devices For Vascular Intervention, Inc. | Atherectomy device having a flexible housing |
US4979951A (en) | 1984-05-30 | 1990-12-25 | Simpson John B | Atherectomy device and method |
USRE33258E (en) | 1984-07-23 | 1990-07-10 | Surgical Dynamics Inc. | Irrigating, cutting and aspirating system for percutaneous surgery |
US4696298A (en) | 1985-11-19 | 1987-09-29 | Storz Instrument Company | Vitrectomy cutting mechanism |
US4771774A (en) | 1986-02-28 | 1988-09-20 | Devices For Vascular Intervention, Inc. | Motor drive unit |
US4669469A (en) | 1986-02-28 | 1987-06-02 | Devices For Vascular Intervention | Single lumen atherectomy catheter device |
US4817613A (en) | 1987-07-13 | 1989-04-04 | Devices For Vascular Intervention, Inc. | Guiding catheter |
US4819635A (en) | 1987-09-18 | 1989-04-11 | Henry Shapiro | Tubular microsurgery cutting apparatus |
US5047040A (en) | 1987-11-05 | 1991-09-10 | Devices For Vascular Intervention, Inc. | Atherectomy device and method |
US5053044A (en) | 1988-01-11 | 1991-10-01 | Devices For Vascular Intervention, Inc. | Catheter and method for making intravascular incisions |
US4850957A (en) | 1988-01-11 | 1989-07-25 | American Biomed, Inc. | Atherectomy catheter |
US5071425A (en) | 1988-09-12 | 1991-12-10 | Devices For Vascular Intervention, Inc. | Atherectomy catheter and method of forming the same |
GB8829182D0 (en) | 1988-12-14 | 1989-01-25 | Univ Birmingham | Surgical instrument |
US4966604A (en) | 1989-01-23 | 1990-10-30 | Interventional Technologies Inc. | Expandable atherectomy cutter with flexibly bowed blades |
US4986807A (en) | 1989-01-23 | 1991-01-22 | Interventional Technologies, Inc. | Atherectomy cutter with radially projecting blade |
US5087265A (en) | 1989-02-17 | 1992-02-11 | American Biomed, Inc. | Distal atherectomy catheter |
US5431673A (en) | 1989-02-17 | 1995-07-11 | American Biomed, Inc. | Distal atherectomy catheter |
US4994067A (en) | 1989-02-17 | 1991-02-19 | American Biomed, Inc. | Distal atherectomy catheter |
US5269793A (en) | 1989-07-20 | 1993-12-14 | Devices For Vascular Intervention, Inc. | Guide wire systems for intravascular catheters |
US5282484A (en) | 1989-08-18 | 1994-02-01 | Endovascular Instruments, Inc. | Method for performing a partial atherectomy |
US5226909A (en) | 1989-09-12 | 1993-07-13 | Devices For Vascular Intervention, Inc. | Atherectomy device having helical blade and blade guide |
US5505210A (en) | 1989-11-06 | 1996-04-09 | Mectra Labs, Inc. | Lavage with tissue cutting cannula |
US5916210A (en) | 1990-01-26 | 1999-06-29 | Intraluminal Therapeutics, Inc. | Catheter for laser treatment of atherosclerotic plaque and other tissue abnormalities |
US5084010A (en) | 1990-02-20 | 1992-01-28 | Devices For Vascular Intervention, Inc. | System and method for catheter construction |
US5092873A (en) | 1990-02-28 | 1992-03-03 | Devices For Vascular Intervention, Inc. | Balloon configuration for atherectomy catheter |
US5222966A (en) | 1990-02-28 | 1993-06-29 | Devices For Vascular Intervention, Inc. | Balloon connection and inflation lumen for atherectomy catheter |
US5154724A (en) | 1990-05-14 | 1992-10-13 | Andrews Winston A | Atherectomy catheter |
US5100424A (en) | 1990-05-21 | 1992-03-31 | Cardiovascular Imaging Systems, Inc. | Intravascular catheter having combined imaging abrasion head |
US5674232A (en) | 1990-06-05 | 1997-10-07 | Halliburton; Alexander George | Catheter and method of use thereof |
US5181920A (en) | 1990-06-08 | 1993-01-26 | Devices For Vascular Intervention, Inc. | Atherectomy device with angioplasty balloon and method |
US5250065A (en) | 1990-09-11 | 1993-10-05 | Mectra Labs, Inc. | Disposable lavage tip assembly |
US5242460A (en) | 1990-10-25 | 1993-09-07 | Devices For Vascular Intervention, Inc. | Atherectomy catheter having axially-disposed cutting edge |
WO1992019930A1 (en) | 1991-04-29 | 1992-11-12 | Massachusetts Institute Of Technology | Method and apparatus for optical imaging and measurement |
US5217474A (en) | 1991-07-15 | 1993-06-08 | Zacca Nadim M | Expandable tip atherectomy method and apparatus |
US5285795A (en) | 1991-09-12 | 1994-02-15 | Surgical Dynamics, Inc. | Percutaneous discectomy system having a bendable discectomy probe and a steerable cannula |
US5224949A (en) | 1992-01-13 | 1993-07-06 | Interventional Technologies, Inc. | Camming device |
US5250059A (en) | 1992-01-22 | 1993-10-05 | Devices For Vascular Intervention, Inc. | Atherectomy catheter having flexible nose cone |
US5318032A (en) | 1992-02-05 | 1994-06-07 | Devices For Vascular Intervention | Guiding catheter having soft tip |
US5224488A (en) | 1992-08-31 | 1993-07-06 | Neuffer Francis H | Biopsy needle with extendable cutting means |
US5383460A (en) | 1992-10-05 | 1995-01-24 | Cardiovascular Imaging Systems, Inc. | Method and apparatus for ultrasound imaging and atherectomy |
US5643297A (en) | 1992-11-09 | 1997-07-01 | Endovascular Instruments, Inc. | Intra-artery obstruction clearing apparatus and methods |
US5372602A (en) | 1992-11-30 | 1994-12-13 | Device For Vascular Intervention, Inc. | Method of removing plaque using catheter cutter with torque control |
US5584842A (en) | 1992-12-02 | 1996-12-17 | Intramed Laboratories, Inc. | Valvulotome and method of using |
US5620447A (en) | 1993-01-29 | 1997-04-15 | Smith & Nephew Dyonics Inc. | Surgical instrument |
US5318528A (en) | 1993-04-13 | 1994-06-07 | Advanced Surgical Inc. | Steerable surgical devices |
US5429136A (en) | 1993-04-21 | 1995-07-04 | Devices For Vascular Intervention, Inc. | Imaging atherectomy apparatus |
US5429138A (en) * | 1993-06-03 | 1995-07-04 | Kormed, Inc. | Biopsy needle with sample retaining means |
US5514115A (en) | 1993-07-07 | 1996-05-07 | Device For Vascular Intervention, Inc. | Flexible housing for intracorporeal use |
US5527325A (en) | 1993-07-09 | 1996-06-18 | Device For Vascular Intervention, Inc. | Atherectomy catheter and method |
US5419774A (en) | 1993-07-13 | 1995-05-30 | Scimed Life Systems, Inc. | Thrombus extraction device |
US5395313A (en) | 1993-08-13 | 1995-03-07 | Naves; Neil H. | Reciprocating arthroscopic shaver |
US5441510A (en) | 1993-09-01 | 1995-08-15 | Technology Development Center | Bi-axial cutter apparatus for catheter |
US5507760A (en) | 1993-11-09 | 1996-04-16 | Devices For Vascular Intervention, Inc. | Cutter device |
AU1399995A (en) | 1993-12-09 | 1995-06-27 | Devices For Vascular Intervention, Inc. | Composite drive shaft |
US5624457A (en) | 1994-04-07 | 1997-04-29 | Devices For Vascular Intervention | Directional atherectomy device with flexible housing |
US5507795A (en) | 1994-04-29 | 1996-04-16 | Devices For Vascular Intervention, Inc. | Catheter with perfusion system |
US5632764A (en) * | 1994-07-14 | 1997-05-27 | Symbiosis Corporation | Snap fit collar for coupling the end of a flexible coil to the actuator or clevis of an endoscopic surgical instrument and an endoscopic surgical instrument incorporating the same |
US5571130A (en) | 1994-10-04 | 1996-11-05 | Advanced Cardiovascular Systems, Inc. | Atherectomy and prostectomy system |
US5491524A (en) | 1994-10-05 | 1996-02-13 | Carl Zeiss, Inc. | Optical coherence tomography corneal mapping apparatus |
US5549601A (en) | 1994-10-11 | 1996-08-27 | Devices For Vascular Intervention, Inc. | Delivery of intracorporeal probes |
US5643296A (en) | 1994-12-16 | 1997-07-01 | Devices For Vasclar Intervention | Intravascular catheter with guiding structure |
US5836957A (en) | 1994-12-22 | 1998-11-17 | Devices For Vascular Intervention, Inc. | Large volume atherectomy device |
US5632754A (en) | 1994-12-23 | 1997-05-27 | Devices For Vascular Intervention | Universal catheter with interchangeable work element |
US6027450A (en) | 1994-12-30 | 2000-02-22 | Devices For Vascular Intervention | Treating a totally or near totally occluded lumen |
US5700687A (en) | 1995-01-30 | 1997-12-23 | Bedminster Bioconversion Corporation | Odor control system |
US6283951B1 (en) | 1996-10-11 | 2001-09-04 | Transvascular, Inc. | Systems and methods for delivering drugs to selected locations within the body |
IL151563A0 (en) | 1995-10-13 | 2003-04-10 | Transvascular Inc | A longitudinal compression apparatus for compressing tissue |
US6302875B1 (en) | 1996-10-11 | 2001-10-16 | Transvascular, Inc. | Catheters and related devices for forming passageways between blood vessels or other anatomical structures |
US6375615B1 (en) | 1995-10-13 | 2002-04-23 | Transvascular, Inc. | Tissue penetrating catheters having integral imaging transducers and their methods of use |
KR0163827B1 (en) * | 1995-10-23 | 1998-12-15 | 김중한 | Tweezer combined with gauge |
US5989281A (en) | 1995-11-07 | 1999-11-23 | Embol-X, Inc. | Cannula with associated filter and methods of use during cardiac surgery |
US5868685A (en) | 1995-11-14 | 1999-02-09 | Devices For Vascular Intervention | Articulated guidewire |
US5733296A (en) | 1996-02-06 | 1998-03-31 | Devices For Vascular Intervention | Composite atherectomy cutter |
US5695506A (en) | 1996-02-06 | 1997-12-09 | Devices For Vascular Intervention | Catheter device with a flexible housing |
US5709698A (en) | 1996-02-26 | 1998-01-20 | Linvatec Corporation | Irrigating/aspirating shaver blade assembly |
US6036707A (en) | 1996-03-07 | 2000-03-14 | Devices For Vascular Intervention | Catheter device having a selectively flexible housing |
US5819738A (en) | 1996-07-03 | 1998-10-13 | Symbiosis Corporation | Jaw assembly having progressively larger teeth and endoscopic biopsy forceps instrument incorporating same |
US5968064A (en) | 1997-02-28 | 1999-10-19 | Lumend, Inc. | Catheter system for treating a vascular occlusion |
US5741270A (en) | 1997-02-28 | 1998-04-21 | Lumend, Inc. | Manual actuator for a catheter system for treating a vascular occlusion |
US6217549B1 (en) | 1997-02-28 | 2001-04-17 | Lumend, Inc. | Methods and apparatus for treating vascular occlusions |
US6010449A (en) | 1997-02-28 | 2000-01-04 | Lumend, Inc. | Intravascular catheter system for treating a vascular occlusion |
US6120516A (en) | 1997-02-28 | 2000-09-19 | Lumend, Inc. | Method for treating vascular occlusion |
US5843103A (en) | 1997-03-06 | 1998-12-01 | Scimed Life Systems, Inc. | Shaped wire rotational atherectomy device |
KR100546223B1 (en) | 1997-04-30 | 2006-01-26 | 마루하 주식회사 | Method for detecting or predicting ischemic diseases |
US5911734A (en) | 1997-05-08 | 1999-06-15 | Embol-X, Inc. | Percutaneous catheter and guidewire having filter and medical device deployment capabilities |
US5954745A (en) | 1997-05-16 | 1999-09-21 | Gertler; Jonathan | Catheter-filter set having a compliant seal |
US6048349A (en) | 1997-07-09 | 2000-04-11 | Intraluminal Therapeutics, Inc. | Systems and methods for guiding a medical instrument through a body |
US6013072A (en) | 1997-07-09 | 2000-01-11 | Intraluminal Therapeutics, Inc. | Systems and methods for steering a catheter through body tissue |
US6193676B1 (en) | 1997-10-03 | 2001-02-27 | Intraluminal Therapeutics, Inc. | Guide wire assembly |
US5951482A (en) | 1997-10-03 | 1999-09-14 | Intraluminal Therapeutics, Inc. | Assemblies and methods for advancing a guide wire through body tissue |
US6083093A (en) * | 1997-10-29 | 2000-07-04 | Williams; Roger S. | Apparatus and process for handling strands of meat product links |
US6183432B1 (en) | 1997-11-13 | 2001-02-06 | Lumend, Inc. | Guidewire and catheter with rotating and reciprocating symmetrical or asymmetrical distal tip |
US5938671A (en) | 1997-11-14 | 1999-08-17 | Reflow, Inc. | Recanalization apparatus and devices for use therein and method |
US6330884B1 (en) | 1997-11-14 | 2001-12-18 | Transvascular, Inc. | Deformable scaffolding multicellular stent |
US6027514A (en) | 1997-12-17 | 2000-02-22 | Fox Hollow Technologies, Inc. | Apparatus and method for removing occluding material from body lumens |
US6217527B1 (en) | 1998-09-30 | 2001-04-17 | Lumend, Inc. | Methods and apparatus for crossing vascular occlusions |
US6231546B1 (en) | 1998-01-13 | 2001-05-15 | Lumend, Inc. | Methods and apparatus for crossing total occlusions in blood vessels |
US6081738A (en) | 1998-01-15 | 2000-06-27 | Lumend, Inc. | Method and apparatus for the guided bypass of coronary occlusions |
AU1927399A (en) | 1998-01-16 | 1999-08-02 | Lumend, Inc. | Catheter apparatus for treating arterial occlusions |
US6038707A (en) * | 1998-01-23 | 2000-03-21 | Smith Sport Optics | Sports goggle having a ventilating fan |
US6134033A (en) | 1998-02-26 | 2000-10-17 | Tyco Submarine Systems Ltd. | Method and apparatus for improving spectral efficiency in wavelength division multiplexed transmission systems |
US6398798B2 (en) | 1998-02-28 | 2002-06-04 | Lumend, Inc. | Catheter system for treating a vascular occlusion |
AUPP379698A0 (en) * | 1998-06-01 | 1998-06-25 | Hull, Peter Hugh | Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions |
US6106515A (en) | 1998-08-13 | 2000-08-22 | Intraluminal Therapeutics, Inc. | Expandable laser catheter |
US6241744B1 (en) | 1998-08-14 | 2001-06-05 | Fox Hollow Technologies, Inc. | Apparatus for deploying a guidewire across a complex lesion |
US6022362A (en) | 1998-09-03 | 2000-02-08 | Rubicor Medical, Inc. | Excisional biopsy devices and methods |
US6228076B1 (en) | 1999-01-09 | 2001-05-08 | Intraluminal Therapeutics, Inc. | System and method for controlling tissue ablation |
US6191862B1 (en) | 1999-01-20 | 2001-02-20 | Lightlab Imaging, Llc | Methods and apparatus for high speed longitudinal scanning in imaging systems |
US6126649A (en) | 1999-06-10 | 2000-10-03 | Transvascular, Inc. | Steerable catheter with external guidewire as catheter tip deflector |
US6445939B1 (en) | 1999-08-09 | 2002-09-03 | Lightlab Imaging, Llc | Ultra-small optical probes, imaging optics, and methods for using same |
US6231549B1 (en) | 1999-08-17 | 2001-05-15 | Sherwood Services, Ag | Shim device for enteral feeding system |
US6299622B1 (en) | 1999-08-19 | 2001-10-09 | Fox Hollow Technologies, Inc. | Atherectomy catheter with aligned imager |
US20030125757A1 (en) | 2000-12-20 | 2003-07-03 | Fox Hollow Technologies, Inc. | Debulking catheters and methods |
US7708749B2 (en) | 2000-12-20 | 2010-05-04 | Fox Hollow Technologies, Inc. | Debulking catheters and methods |
US6447525B2 (en) | 1999-08-19 | 2002-09-10 | Fox Hollow Technologies, Inc. | Apparatus and methods for removing material from a body lumen |
US6638233B2 (en) | 1999-08-19 | 2003-10-28 | Fox Hollow Technologies, Inc. | Apparatus and methods for material capture and removal |
US7713279B2 (en) | 2000-12-20 | 2010-05-11 | Fox Hollow Technologies, Inc. | Method and devices for cutting tissue |
US8328829B2 (en) | 1999-08-19 | 2012-12-11 | Covidien Lp | High capacity debulking catheter with razor edge cutting window |
US20030120295A1 (en) | 2000-12-20 | 2003-06-26 | Fox Hollow Technologies, Inc. | Debulking catheters and methods |
CA2281457A1 (en) * | 1999-08-26 | 2001-02-26 | Alfred Ernest Bassett | Securing device for intraveneous cannula or catheter |
US6394976B1 (en) | 2000-01-31 | 2002-05-28 | Intraluminal Therapeutics, Inc. | Catheter for controlling the advancement of a guide wire |
EP1294441A2 (en) * | 2000-06-14 | 2003-03-26 | Medtronic, Inc. | Deep computing applications in medical device systems |
US7699790B2 (en) | 2000-12-20 | 2010-04-20 | Ev3, Inc. | Debulking catheters and methods |
ATE499054T1 (en) | 2000-12-20 | 2011-03-15 | Fox Hollow Technologies Inc | REDUCTION CATHETER |
US20060032508A1 (en) | 2000-12-20 | 2006-02-16 | Fox Hollow Technologies, Inc. | Method of evaluating a treatment for vascular disease |
US20050154407A1 (en) * | 2000-12-20 | 2005-07-14 | Fox Hollow Technologies, Inc. | Method of evaluating drug efficacy for treating atherosclerosis |
US20040167554A1 (en) | 2000-12-20 | 2004-08-26 | Fox Hollow Technologies, Inc. | Methods and devices for reentering a true lumen from a subintimal space |
US20100121360A9 (en) | 2000-12-20 | 2010-05-13 | Fox Hollow Technologies, Inc | Testing a patient population having a cardiovascular condition for drug efficacy |
US20060235366A1 (en) | 2000-12-20 | 2006-10-19 | Fox Hollow Technologies, Inc. | Method of evaluating a treatment for vascular disease |
US6428552B1 (en) | 2001-01-22 | 2002-08-06 | Lumend, Inc. | Method and apparatus for crossing intravascular occlusions |
US7156859B2 (en) * | 2001-07-23 | 2007-01-02 | Fos Holding S.A. | Device for separating the epithelium layer from the surface of the cornea of an eye |
CA2457775A1 (en) | 2001-08-20 | 2003-02-27 | Biosite Incorporated | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20070077614A1 (en) | 2003-04-01 | 2007-04-05 | Wolfert Robert L | Uses of lp-pla2 in combination to assess coronary risk |
US9171129B2 (en) | 2004-02-10 | 2015-10-27 | Todd J. Cohen | System and method for storing, accessing, and displaying specialized patient information and other medical information |
-
2005
- 2005-09-21 US US11/230,924 patent/US7794413B2/en not_active Expired - Fee Related
-
2006
- 2006-09-21 CA CA002622716A patent/CA2622716A1/en not_active Abandoned
- 2006-09-21 WO PCT/US2006/036952 patent/WO2007035909A2/en active Application Filing
- 2006-09-21 EP EP06825062A patent/EP1938196A4/en not_active Withdrawn
-
2010
- 2010-09-10 US US12/880,010 patent/US20110060606A1/en not_active Abandoned
-
2012
- 2012-09-11 US US13/609,537 patent/US20130013216A1/en not_active Abandoned
Patent Citations (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5306244A (en) * | 1984-05-14 | 1994-04-26 | Surgical Systems & Instruments, Inc. | Method of guidewire insertion |
US4646736A (en) * | 1984-09-10 | 1987-03-03 | E. R. Squibb & Sons, Inc. | Transluminal thrombectomy apparatus |
US5226910A (en) * | 1989-07-05 | 1993-07-13 | Kabushiki Kaisha Topcon | Surgical cutter |
US5580722A (en) * | 1989-07-18 | 1996-12-03 | Oncogene Science, Inc. | Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease |
US5376632A (en) * | 1990-01-29 | 1994-12-27 | Konings; Frank J. | Cyclodextrin based erythropoietin formulation |
US5336616A (en) * | 1990-09-12 | 1994-08-09 | Lifecell Corporation | Method for processing and preserving collagen-based tissues for transplantation |
US5731489A (en) * | 1991-08-14 | 1998-03-24 | Detlev Ganten | Transgenic rats containing at least one human gene which participates in blood pressure control |
US6017960A (en) * | 1992-03-31 | 2000-01-25 | Regents Of The University Of Michigan | Method of treating post-inflammatory hyperpigmentation in black skin with a retinoid, and method of lightening black skin with a retinoid |
US5406959A (en) * | 1992-06-22 | 1995-04-18 | Mann; David | Method and apparatus for obtaining an arterial biopsy and for diagnosting diseases of the vascular system |
US5538504A (en) * | 1992-07-14 | 1996-07-23 | Scimed Life Systems, Inc. | Intra-extravascular drug delivery catheter and method |
US5571122A (en) * | 1992-11-09 | 1996-11-05 | Endovascular Instruments, Inc. | Unitary removal of plaque |
US5595722A (en) * | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
US5535756A (en) * | 1994-01-06 | 1996-07-16 | Parasher; Vinod K. | Catheter with simultaneous brush cytology and scrape biopsy capability |
US20060024323A1 (en) * | 1994-02-09 | 2006-02-02 | Epitopix, Llc | Active immunization using a siderophore receptor protein |
US5803078A (en) * | 1994-05-06 | 1998-09-08 | Brauner; Mark E. | Methods and apparatus for intrapulmonary therapy and drug administration |
US5626562A (en) * | 1994-11-28 | 1997-05-06 | Devices For Vascular Intervention | Drug delivery catheter |
US5865794A (en) * | 1994-11-28 | 1999-02-02 | Devices For Vascular Intervention | Drug delivery catheter |
US6068638A (en) * | 1995-10-13 | 2000-05-30 | Transvascular, Inc. | Device, system and method for interstitial transvascular intervention |
US6283983B1 (en) * | 1995-10-13 | 2001-09-04 | Transvascular, Inc. | Percutaneous in-situ coronary bypass method and apparatus |
US5843000A (en) * | 1996-05-07 | 1998-12-01 | The General Hospital Corporation | Optical biopsy forceps and method of diagnosing tissue |
US6544276B1 (en) * | 1996-05-20 | 2003-04-08 | Medtronic Ave. Inc. | Exchange method for emboli containment |
US5796861A (en) * | 1996-07-12 | 1998-08-18 | Frim International, Inc. | Mosaic construction, processing, and review of very large electronic micrograph composites |
US6355451B1 (en) * | 1996-11-27 | 2002-03-12 | Boston Heart Foundation, Inc. | Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
US6419625B1 (en) * | 1997-01-03 | 2002-07-16 | Robin G. Smith | Methods and devices for ex vivo irradiation of autologous coronary bypass conduit |
US5941869A (en) * | 1997-02-12 | 1999-08-24 | Prolifix Medical, Inc. | Apparatus and method for controlled removal of stenotic material from stents |
US6524795B1 (en) * | 1997-03-10 | 2003-02-25 | Interleukin Genetics, Inc. | Diagnostics for cardiovascular disorders |
US6534322B1 (en) * | 1997-06-10 | 2003-03-18 | Medlyte Diagnostics, Inc. | Kits for early detection of heart disease |
US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
US6353757B2 (en) * | 1999-05-07 | 2002-03-05 | Cedars-Sinai Medical Center | Method for collecting data pertinent to predictors of heart arrhythmias using an animal test subject |
US20040030320A1 (en) * | 1999-06-02 | 2004-02-12 | Boston Scientific Corporation | Devices and methods for delivering a drug |
US6423742B1 (en) * | 1999-09-02 | 2002-07-23 | Drake Larson | Compositions for reducing vascular plaque formation and methods of using same |
US20010007083A1 (en) * | 1999-12-29 | 2001-07-05 | Roorda Wouter E. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
US20060024234A1 (en) * | 2000-06-02 | 2006-02-02 | Large Scale Proteomics Corporation, A Division Of Large Scale Biology Corporation | Protein markers for pharmaceuticals and related toxicity |
US20020072484A1 (en) * | 2000-09-20 | 2002-06-13 | Alters Susan E. | Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders |
US20030100486A1 (en) * | 2000-12-14 | 2003-05-29 | Ridker Paul M. | Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes |
US20030125758A1 (en) * | 2000-12-20 | 2003-07-03 | Fox Hollow Technologies, Inc. | Debulking catheters and methods |
US20060239982A1 (en) * | 2000-12-20 | 2006-10-26 | Fox Hollow Technologies, Inc. | Debulking catheters and methods |
US20050222519A1 (en) * | 2000-12-20 | 2005-10-06 | Fox Hollow Technologies, Inc. | Debulking catheters and methods |
US6962776B2 (en) * | 2001-02-23 | 2005-11-08 | Mayo Foundation For Medical Education And Research | Methods and materials for evaluating cardiovascular conditions |
US20030032936A1 (en) * | 2001-08-10 | 2003-02-13 | Lederman Robert J. | Side-exit catheter and method for its use |
US20040209307A1 (en) * | 2001-08-20 | 2004-10-21 | Biosite Incorporated | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20030064522A1 (en) * | 2001-09-14 | 2003-04-03 | Alan Kleinfeld | Diagnostic markers for ischemia |
US6904434B1 (en) * | 2001-12-18 | 2005-06-07 | Siebel Systems, Inc. | Method and system for providing real-time clinical trial enrollment data |
US20030219813A1 (en) * | 2002-04-05 | 2003-11-27 | Millennium Pharmaceuticals, Inc. | Identification of a family of secreted proteins in vascular endothelium |
US20040014198A1 (en) * | 2002-05-23 | 2004-01-22 | Craft David L. | Non-revertible beta-oxidation blocked candida tropicalis |
US20040110241A1 (en) * | 2002-12-06 | 2004-06-10 | Segal Mark S. | Materials and methods for monitoring vascular endothelial function |
US20050064516A1 (en) * | 2003-09-18 | 2005-03-24 | Kantor Aaron B. | Biological markers for diagnosing multiple sclerosis |
US20060236019A1 (en) * | 2005-04-19 | 2006-10-19 | Fox Hollow Technologies, Inc. | Libraries and data structures of materials removed by debulking catheters |
US20070218519A1 (en) * | 2005-10-11 | 2007-09-20 | Tethys Bioscience, Inc. | Diabetes-associated markers and methods of use thereof |
US20070173901A1 (en) * | 2006-01-24 | 2007-07-26 | Reeve Helen L | Method and device for detecting and treating depression |
US7989207B2 (en) * | 2006-02-17 | 2011-08-02 | Tyco Healthcare Group Lp | Testing lumenectomy samples for markers of non-vascular diseases |
Also Published As
Publication number | Publication date |
---|---|
US20060236019A1 (en) | 2006-10-19 |
US7794413B2 (en) | 2010-09-14 |
EP1938196A2 (en) | 2008-07-02 |
WO2007035909A2 (en) | 2007-03-29 |
WO2007035909A3 (en) | 2009-05-07 |
EP1938196A4 (en) | 2010-01-06 |
CA2622716A1 (en) | 2007-03-29 |
US20130013216A1 (en) | 2013-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7794413B2 (en) | Libraries and data structures of materials removed by debulking catheters | |
US7989207B2 (en) | Testing lumenectomy samples for markers of non-vascular diseases | |
US20070078469A1 (en) | Testing a patient population having a cardiovascular condition for drug efficacy | |
US20070038173A1 (en) | Methods affecting markers in patients having vascular disease | |
Williams et al. | Clinical role of the renal transplant biopsy | |
US7927784B2 (en) | Vascular lumen debulking catheters and methods | |
EP1871244B1 (en) | Compositions comprising excised vacular tissue | |
US20060032508A1 (en) | Method of evaluating a treatment for vascular disease | |
US20120179178A1 (en) | Method of evaluating a treatment for vascular disease | |
US20050154407A1 (en) | Method of evaluating drug efficacy for treating atherosclerosis | |
US7699790B2 (en) | Debulking catheters and methods | |
Sabin et al. | Predictors of no-reflow during primary angioplasty for acute myocardial infarction, from Medical College Hospital, Trivandrum | |
Sigdel et al. | Assessment of 19 genes and validation of CRM gene panel for quantitative transcriptional analysis of molecular rejection and inflammation in archival kidney transplant biopsies | |
CN113164181A (en) | Device for managing acute ischemic events | |
US20130012411A1 (en) | Testing a patient population having a cardiovascular condition for drug efficacy | |
Lee et al. | Histopathologic findings of vascular damage after mechanical thrombectomy using stent retriever in canine models | |
Olausson et al. | Long-term transplant function after thrombolytic treatment ex vivo of donated kidneys retrieved 4 to 5 h after circulatory death | |
Grankvist | Development of Superselective Endovascular Tissue Access and Sampling | |
Eikmans et al. | Messenger RNA assessment in clinical nephrology: perspectives and progress of methodology | |
Class et al. | Patent application title: TESTING LUMENECTOMY SAMPLES FOR MARKERS OF NON-VASCULAR DISEASES Inventors: Angela Soito (Oakland, CA, US) Angela Soito (Oakland, CA, US) John B. Simpson (Woodside, CA, US) Assignees: Tyco Healthcare Group LP | |
Igual Munoz et al. | P5254 Prognostic value and clinical predictors of Intramyocardial Hemorrhage measured by CMR T2* weighted sequences | |
Kobashigawa | Is it time for a noninvasive test to detect cardiac allograft rejection? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |